Frontlight ResearchEarly access
TerminatedEarly phase 1
Superselective Intra-arterial Cerebral Infusion of Temsirolimus in HGG
Key facts
- Who runs it
- Nader Sanai
- Where
- Phoenix, United StatesSee the site
- Trial code
- Status
- Terminated
- Phase
- Early phase 1
- People taking part
- 5 people enrolled
- Started
- 15 May 2023
- Ended
- 16 Oct 2025
- Type of study
- Interventional
- Treatments tested
- Temsirolimus
- Record updated
- 14 May 2026
- Why it stopped
- Study terminated due to unavailability of the investigational product required to continue the study.
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 20 criteriaShow less
Who can take part
- Histologically diagnosed high-grade glioma (Grade 3 or 4 per 2021 WHO criteria) in the frontal lobe
- Tissue must demonstrate mTOR+: PTEN loss OR PIK3C2B or AKT3 amplification on aCGH OR mutations for PIK3CA or PIK3R1, or mTOR or PTEN mutations using next-generation sequencing analysis OR pS6 positivity on immunohistochemistry (≥30% for pS6)
- Patients who have completed the Stupp regimen
- Have measurable disease pre-operatively, defined as at least 1 contrast enhancing lesion, with 2 perpendicular measurements of at least 1 cm, as per RANO criteria
- Sufficient biopsy or archival tissue to confirm eligibility
- Has voluntarily agreed to participate by giving written informed consent. Written informed consent for the protocol must be obtained prior to any screening procedures. If consent cannot be expressed in writing, it must be formally documented and witnessed, ideally via an independent trusted witness
- Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests and other procedures
- Age ≥18 at time of consent
- Have a performance status (PS) of ≤2 on the Eastern Cooperative Oncology (Group (ECOG) scale
- Participant has adequate bone marrow and organ function
- Confirmed negative serum pregnancy test (β-hCG) before starting study treatment or participant who is no longer of childbearing potential due to surgical, chemical, or natural menopause
- For females of reproductive potential: use of highly effective contraception and agreement to use such a method during study participation until the end of treatment administration and for 3 months after the last dose of study drug
- For males of reproductive potential: use of condoms or other methods to ensure effective contraception with partner until the end of treatment administration and for 3 months after the last dose of study drug
- Agreement to adhere to Lifestyle Considerations throughout study duration
Who cannot take part
- Received a live vaccination or is in close contact with someone who received a live vaccination within 28 days of the start of study treatment
- Treatment with another investigational drug or other intervention within 30 days prior to the planned treatment Day 1
- Past medical history of interstitial lung disease (ILD), drug-induced ILD, radiation pneumonitis which required steroid treatment, or any evidence of clinically active interstitial lung disease
- Known hypersensitivity to temsirolimus or its metabolites, polysorbate 80, or to any other component of temsirolimus
- Participant has serious and/or uncontrolled preexisting medical condition(s) that, in the judgment of the investigator, would preclude participation in this study (for example, active infection, interstitial lung disease, severe dyspnea at rest or requiring oxygen therapy, severe renal impairment [e.g. estimated creatinine clearance]
- Pregnancy or lactation
Where in United States
- St. Joseph's Hospital and Medical CenterPhoenix, United States
About the trial
What the trial wants to find out
This is a single-center, open-label, dose-escalating Phase 0 trial that will enroll participants with a confirmed diagnosed recurrent high-grade glioma (grade 3 or 4 per WHO criteria) targeting the mTOR pathway. Eligible participants will be administered a single infusion of temsirolimus through super-selective intra-arterial infusion or intravenous infusion. Participants will receive the study drug administration on the same day as the planned surgical resection of the tumor.
The group in the trial
- Single infusion of TemsirolimusTreatment being tested
Single infusion of Temsirolimus via super-selective intra-arterial infusion or IV
Treatment: Temsirolimus
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Phase 0, Single-center, Open-label, Dose-escalating Trial Using Super-selective Intra-arterial Infusion of a Single Dose of Temsirolimus for the Treatment of Recurrent High-grade Glioma
- Record updated
- 14 May 2026